CV Therapeutics Inc - Current report filing (8-K)
June 24 2008 - 1:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): 06/24/2008
CV THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-21643
Delaware
|
|
43-1570294
|
(State or other jurisdiction of
|
|
(IRS Employer
|
incorporation)
|
|
Identification No.)
|
3172 Porter Drive, Palo Alto, CA 94304
(Address of principal executive offices, including zip code)
650-384-8500
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On June 24, 2008, we publicly disseminated a press release announcing that in conjunction with the commercial launch of Lexiscan(TM) (regadenoson) injection by Astellas Pharma US, Inc. in the United States, CV Therapeutics has earned a milestone payment of $10 million from TPG-Axon Capital, through an affiliated entity. CV Therapeutics will recognize the milestone as revenue earned in the second quarter of 2008.
The foregoing description is qualified in its entirety by reference to our press release dated June 23, 2008, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
* * * * *
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
99.1 Press Release dated June 24, 2008.
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
|
|
CV THERAPEUTICS, INC.
|
|
|
Date: June 24, 2008
|
|
|
|
By:
|
|
/s/ TRICIA BORGA SUVARI
|
|
|
|
|
|
|
|
|
TRICIA BORGA SUVARI
|
|
|
|
|
|
|
|
|
Senior Vice President and General Counsel
|
|
|
Exhibit Index
Exhibit No.
|
|
Description
|
EX-99.1
|
|
Press Release dated June 24, 2008.
|
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024
See More Message Board Posts